News

Deal Announcements

Arsanis Nets New Debt Financing

Monday, January 4, 2016 5:53:00 AM PDT | VentureDeal
   Waltham, Massachusetts  --  Biotechnology company Arsanis has landed $4 million in venture capital debt funding, according to an SEC filing.

Arsanis is developing fully human monoclonal antibodies that operate against severe infectious diseases.

Investors in the financing weren't disclosed in the filing.

A total of eight investors participated in the offering.

The company did not say how the funding proceeds would be used.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1